These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30412791)

  • 1. Post-translational modifications of Parkinson's disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination.
    Junqueira SC; Centeno EGZ; Wilkinson KA; Cimarosti H
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2001-2007. PubMed ID: 30412791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting α-synuclein post-translational modifications in Parkinson's disease.
    Canever JB; Soares ES; de Avelar NCP; Cimarosti HI
    Behav Brain Res; 2023 Feb; 439():114204. PubMed ID: 36372243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
    He S; Wang F; Yung KKL; Zhang S; Qu S
    ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-translational modification and mitochondrial function in Parkinson's disease.
    Luo S; Wang D; Zhang Z
    Front Mol Neurosci; 2023; 16():1329554. PubMed ID: 38273938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
    Chen H; Zhao YF; Chen YX; Li YM
    ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease.
    Mishra T; Singh S; Singh TG
    Cell Mol Neurobiol; 2024 Jul; 44(1):53. PubMed ID: 38960968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the Role of Aberrant Protein Post-Translational Modification in the Pathology of Neurodegeneration.
    Shafi S; Singh A; Gupta P; Chawla PA; Fayaz F; Sharma A; Pottoo FH
    CNS Neurol Disord Drug Targets; 2021; 20(1):54-67. PubMed ID: 32885763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-translational Modifications in Parkinson's Disease.
    Antunes ASLM
    Adv Exp Med Biol; 2022; 1382():85-94. PubMed ID: 36029405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Technologies Unraveling the Significance of Post-Translational Modifications (PTMs) as Crucial Players in Neurodegeneration.
    Zafar S; Fatima SI; Schmitz M; Zerr I
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
    Oueslati A; Fournier M; Lashuel HA
    Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-translational modifications: Regulators of neurodegenerative proteinopathies.
    Gupta R; Sahu M; Srivastava D; Tiwari S; Ambasta RK; Kumar P
    Ageing Res Rev; 2021 Jul; 68():101336. PubMed ID: 33775891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Analysis Indicates That PARP1 Acts as a Histone Deacetylases Interactor Sharing Common Lysine Residues for Acetylation, Ubiquitination, and SUMOylation in Alzheimer's and Parkinson's Disease.
    Gupta R; Kumar P
    ACS Omega; 2021 Mar; 6(8):5739-5753. PubMed ID: 33681613
    [No Abstract]   [Full Text] [Related]  

  • 14. Protein Language: Post-Translational Modifications Talking to Each Other.
    Vu LD; Gevaert K; De Smet I
    Trends Plant Sci; 2018 Dec; 23(12):1068-1080. PubMed ID: 30279071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications.
    Durcan TM; Fon EA
    Genes Dev; 2015 May; 29(10):989-99. PubMed ID: 25995186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post translational modifications at the verge of plant-geminivirus interaction.
    Prasad A; Sharma S; Prasad M
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194983. PubMed ID: 37717937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
    Lee YC; Hsu SD
    Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone induced Warburg effect in HEK293 cells is associated with post-translational modifications and proteasomal degradation of progesterone receptor membrane component 1.
    Sabbir MG
    J Steroid Biochem Mol Biol; 2019 Jul; 191():105376. PubMed ID: 31067491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifications in the cellular proteome and their clinical application.
    Elguero B; Gonilski Pacin D; Cárdenas Figueroa C; Fuertes M; Arzt E
    Medicina (B Aires); 2019; 79(Spec 6/1):570-575. PubMed ID: 31864228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of post-translational modifications in cardiovascular pathologies: Focus on SUMOylation, neddylation, succinylation, and prenylation.
    Gao J; Shao K; Chen X; Li Z; Liu Z; Yu Z; Aung LHH; Wang Y; Li P
    J Mol Cell Cardiol; 2020 Jan; 138():49-58. PubMed ID: 31751566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.